313 related articles for article (PubMed ID: 29503112)
1. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
Cutland CL; Nolan T; Halperin SA; Kurugol Z; Ahmed K; Perrett KP; Richmond P; Marshall HS; Ceyhan M; Kolhe D; Hezareh M; Van Der Wielen M
Vaccine; 2018 Mar; 36(14):1908-1916. PubMed ID: 29503112
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
Ruiz-Palacios GM; Huang LM; Lin TY; Hernandez L; Guerrero ML; Villalobos AL; Van der Wielen M; Moreira M; Fissette L; Borys D; Miller JM
Pediatr Infect Dis J; 2013 Jan; 32(1):62-71. PubMed ID: 23076383
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
7. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
Cutland CL; Peyrani P; Webber C; Newton R; Cutler M; Perez JL
Vaccine; 2023 Jan; 41(5):1153-1160. PubMed ID: 36621408
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y
Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
[TBL] [Abstract][Full Text] [Related]
14. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial.
Block SL; Shepard J; Garfield H; Xie F; Han L; Dull PM; Smolenov I
Pediatr Infect Dis J; 2016 Feb; 35(2):e48-59. PubMed ID: 26479973
[TBL] [Abstract][Full Text] [Related]
16. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
17. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
